This is a multi-center randomized phase III clinical study of first-line intravenous FOLFOX plus Camrelizumab and apatinib versus HAIC-FOLFOX plus Camrelizumab and apatinib for BCLC C stage hepatocellular carcinoma.
Age 18-75, male or female;
The clinical diagnosis conforms to primary hepatocellular carcinoma (HCC) and the lesion conforms to BCLC stage C.
Child-pugh liver function grading: Grade A or B
Did not received any type of other first-line drugs such as Sorafenib
Have received immunotherapeutic drugs or interferon in the past.
Severe allergic reaction to other monoclonal antibodies, immunotherapy or chemotherapy.
Female subjects with pregnancy or on feeding.
Patients with congenital or acquired immune deficiencies.